Purigen Launches New Extraction and Purification Kit that Enables Scientists to Maximize Usable DNA from Limited Biological Samples

Automated Ionic® Cells to Pure DNA Low Input Kit consistently recovers up to twice the amount of high-quality nucleic acid from as few as 10 cultured or sorted cells

Purigen Biosystems, Inc., a leading provider of next-generation technologies for extracting and purifying nucleic acids from biological samples, today announced the launch of the Ionic® Cells to Pure DNA Low Input Kit for researchers working with limited biological samples. The simplified and automated 60-minute workflow delivers high-quality DNA for the rapid investigation of genetic abnormalities or examination of disease treatment effects.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201013005344/en/

The Ionic Cells to Pure DNA Low Input Kit from Purigen Biosystems (Photo: Business Wire)

The Ionic Cells to Pure DNA Low Input Kit offers consistent recovery of DNA with yields near the theoretical maximum for as many as 100,000 down to as few as 10 cultured or sorted cells. Compared to leading column-based products, the new kit delivers up to twice the amount of DNA with a significantly higher proportion greater than 20 kb in length. Regardless of the input amount, the workflow is the same and does not require carrier RNA. The prepared DNA is ready for analysis by downstream techniques such as next-generation sequencing (NGS) or qPCR.

The Ionic® Cells to Pure DNA Low Input Kit uses Purigen’s innovative isotachophoresis-based (ITP) technology, which is incorporated into its Ionic® Purification System, a compact benchtop instrument that enables the automated extraction of pure and abundant nucleic acids from a wide range of sample types. Biological samples are gently lysed and then loaded into the Ionic® Fluidic Chip. The Ionic System applies an electric field to the chip, and nucleic acids are isolated in their natural, native form using ITP technology. The nucleic acids are not denatured or dehydrated, nor are they bound and stripped from fixed surfaces. The process minimizes fragmentation and eliminates any bead or buffer contamination.

“Unlocking the genetic information stored within precious and limited samples has been a longstanding challenge for genomic researchers,” said Barney Saunders, PhD, CEO of Purigen Biosystems. “Unlike conventional technologies, the Ionic Purification System’s performance does not decline with limited sample input. The Ionic Cells to Pure DNA Low Input Kit simplifies the extraction process, accelerates turnaround times, and improves yields of pure, abundant, and ready-to-sequence DNA from limited sample quantities.”

The Ionic® Cells to Pure DNA Low Input Kit consists of six chips and a reagent set with all necessary enzymes and buffers to perform DNA extraction from 48 samples. The kit is available now through Purigen’s direct sales channels. For more information, please visit: https://www.purigenbio.com/applications/ionic-cells-pure-dna.

About Purigen Biosystems

Purigen Biosystems is redefining nucleic acid sample preparation with an innovative platform based on the highly efficient isotachophoresis technology invented by Juan Santiago, PhD, and his team at Stanford University. Purigen’s automated benchtop instrumentation and accompanying microfluidic chip purify nucleic acid samples from a wide variety of sources, including minute or otherwise challenging cancer samples. The purified nucleic acids are then immediately compatible with a wide range of downstream detection methods, including next-generation sequencing, PCR, and other genomic tests. For more information, visit www.purigenbio.com.

Ionic is a registered trademark of Purigen Biosystems, Inc. All other trademarks are the property of their respective owners. All products described herein are intended FOR RESEARCH USE ONLY and NOT FOR USE IN DIAGNOSTIC PROCEDURES.

View source version on businesswire.com: https://www.businesswire.com/news/home/20201013005344/en/


Andrew Noble
[email protected]

Source Article